Neurocrine Biosciences Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
All right. Good afternoon, everybody. Thanks for joining us. I'm Marc Goodman, one of the biopharma analysts here at SVB Securities. Thanks for joining us at our conference. Very lucky to have the team from Neurocrine joining us here, Kevin Gorman, the CEO; Matt Abernethy, CFO. Everybody knows these guys. Thank you so much for joining us.
Obviously, one of the leaders in the CNS space. If you went back years ago, it was like, well, how big is this tardive dyskinesia drug going to be? And I think we probably started out as even a $500 million drug. And today, the overruns probably moved above $2 billion, and it could even be $2.5 billion right now. It's probably kind of the number that everybody is talking about. But I think also the discussion is, okay, they've done just an amazing job with the first drug. We'd love to see a second job. That's kind of like what we keep here, and I know you all hear it, too, all the time. So Kevin, maybe I'll give you a chance to make some opening
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |